Publications
4895 Results
- Journal / Conference
- Journal of Patient Safety Jan 1;17(1):e28-e34. doi: 10.1097/PTS.0000000000000772; Sep 29. doi: 10.1097/PTS.0000000000000772. Online ahead of print
- Year
- 2021
- Research Committee(s)
- Multiple sites
- PMID
- PMID33003175
- PMC
- PMC7775319
Improvement initiative to develop and implement a tool for detecting drug-drug interactions during oncology clinical trial enrollment eligibility screening
- Journal / Conference
- International Journal of Cancer Jan 1;148(1):99-105. Epub 2020 Sep 24.Sep 15. doi: 10.1002/ijc.33282. Online ahead of print
- Year
- 2021
- Research Committee(s)
- Cancer Control and Prevention
- PMID
- PMID32930425
- Study Number(s)
- S0000, SWOG-9217
African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer
- Journal / Conference
- Lancet Haematology Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22
- Year
- 2021
- Research Committee(s)
- Myeloma
- PMID
- PMID33357482
- Study Number(s)
- S1211
Bortezomib, Lenalidomide, Dexamethasone with or without Elotuzumab for Untreated, High-Risk Myeloma – Primary Analysis of the SWOG-1211 Randomized Phase II Trial
- Journal / Conference
- Nature Genetics Jan 4. doi: 10.1038/s41588-020-00748-0. Online ahead of print.
- Year
- 2021
- Research Committee(s)
- Cancer Control and Prevention
- PMID
- PMID33398198
- Study Number(s)
- S0000, SWOG-9217
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
- Journal / Conference
- Lancet Oncology 2020 Dec;21(12):1620-1629. doi: 10.1016/S1470-2045(20)30527-1.
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID33271092
- PMC
- PMC7786835
- Study Number(s)
- CTSU/C80702
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer: Final results from the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual)
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021501
Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), Poster Presentation and Poster Highlights session
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
Immunologic Predictors of Therapeutic Response to Neoadjuvant Therapy for Pancreatic Adenocarcinoma (PDA) in SWOG S1505
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 3; abstr TPS447); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), poster session
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S2001
S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 3; abstr 10); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), rapid abstract presentation
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study
- Journal / Conference
- J Clin Oncol 39, 2021 (suppl 3; abstr 361); ASCO GI Cancers Symposium (January 15-17, 2021, virtual)
- Year
- 2021
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021202